P/E ratio for Corcept Therapeutics (CORT)
P/E ratio as of April 2024 (TTM): 25.8
According to Corcept Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.75. At the end of 2022 the company had a P/E ratio of 21.4.
P/E ratio history for Corcept Therapeutics from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 21.4 | 4.74% |
| 2021 | 20.4 | -28.21% |
| 2020 | 28.4 | 95.05% |
| 2019 | 14.6 | -29.07% |
| 2018 | 20.6 | 28.6% |
| 2017 | 16.0 | -84.63% |
| 2016 | 104 | -246.14% |
| 2015 | -71.1 | 635.14% |
| 2014 | -9.68 | 38.68% |
| 2013 | -6.98 | 100.08% |
| 2012 | -3.49 | -59.21% |
| 2011 | -8.55 | -13.61% |
| 2010 | -9.90 | 35.29% |
| 2009 | -7.32 | 208.41% |
| 2008 | -2.37 | -73.9% |
| 2007 | -9.09 | 705.38% |
| 2006 | -1.13 | -72.79% |
| 2005 | -4.15 | -40.94% |
| 2004 | -7.02 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -59.82% | 🇺🇸 USA |
 Novartis NVS | 24.8 | -3.88% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -46.99% | 🇺🇸 USA |
 Eli Lilly LLY | 137 | 433.57% | 🇺🇸 USA |
 Merck MRK | 68.7 | 166.97% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.2 | -52.75% | 🇺🇸 USA |
 MannKind Corp MNKD | -21.5 | -183.39% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -0.6631 | -102.58% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 116 | 349.22% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.